Deep brain stimulation may improve long-term quality of life for people with ‘treatment-resistant depression’

Human,Brain,Anatomical,Model,,Front,View

Alex Pike and Jonathan Roiser appraise and summarise a recently study in the Brain Stimulation journal, which looks at the long-term efficacy and quality of life of deep brain stimulation for severe depression.

[read the full story...]

Ketamine “shows promise” as an anti-suicidal ideation agent, but will this promise ever be realised?

sinitta-leunen-aFXiQMUi2zA-unsplash

Rosalind McAlpine and Karel Kieslich summarise a recent systematic review which focuses on the rapid anti-suicidal ideation effect of ketamine.

[read the full story...]

Deep brain stimulation for severe depression: could ‘brain pacemakers’ be the answer for some?

soumitro-joy-1ocglf7UGvQ-unsplash

Alexandra Pike, Alexis An Yee Low and Jonathan Roiser critically appraise a recent n-of-1 study on ‘brain pacemakers for depression’, which received extensive press coverage earlier this month. The case study looks at deep brain stimulation (closed-loop neuromodulation) in an individual with treatment-resistant depression.

[read the full story...]

Can ketamine metabolites and gamma power help predict clinical response for ‘treatment resistant depression’?

girl-with-red-hat-r4A-lJTgXQg-unsplash

Anya Borissova summarises a recent randomised placebo-controlled trial that evaluated ketamine metabolites, clinical response, and gamma power for major depression.

[read the full story...]

Turn on, or tune out? Is psilocybin assisted therapy close to becoming a first-line treatment for depression?

reproductive-health-supplies-coalition-V4pVBEHKPo0-unsplash

James Rucker and Sameer Jauhar summarise a recent RCT on the effectiveness of psilocybin assisted therapy versus escitalopram assisted therapy for major depressive disorder.

[read the full story...]

Patients’ experience of ketamine treatment for depression: the ‘Ketamine and me’ project

shutterstock_562050361

In her debut blog, Harmony Jiang reviews a recent qualitative study exploring patients’ experience and response to ketamine treatment for depression.

[read the full story...]

Psilocybin for treatment-resistant depression: what are the effects on brain activity?

bret-kavanaugh-_af0_qAh4K4-unsplash

Anya Borissova summarises the therapeutic mechanisms of psilocybin in treatment-resistant depression and changes noticed in the amygdala and prefrontal cortex during emotional processing.

[read the full story...]

Ayahuasca-induced increases in brain-derived neurotrophic factor (BNDF) associated with reduced depression

28603239812_e87b743a04_k

Pascal Immanuel Michael summarises a recent RCT, which looks at how a single dose of the psychedelic Ayahuasca may help people with severe depression who have not benefited from more traditional treatment.

[read the full story...]

Intranasal esketamine for treatment-resistant depression: the first clinical study

shutterstock_174166007

Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.

[read the full story...]

Polypharmacy for major depression: is practice evidence-based?

joshua-coleman-623077-unsplash

Jessica Bone reports on a recent cross-sectional study that looks at the clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

[read the full story...]